Fresenius SE & Co KGaA (FRE) Given a €75.00 Price Target by Nord/LB Analysts

Fresenius SE & Co KGaA (FRA:FRE) has been given a €75.00 ($87.21) target price by investment analysts at Nord/LB in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. Nord/LB’s target price would suggest a potential upside of 23.93% from the company’s previous close.

Several other research analysts have also recently commented on FRE. UBS Group set a €59.00 ($68.60) target price on Fresenius SE & Co KGaA and gave the stock a “sell” rating in a research report on Tuesday, June 26th. Sanford C. Bernstein set a €83.00 ($96.51) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. Morgan Stanley set a €77.00 ($89.53) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, July 3rd. Bank of America set a €75.00 ($87.21) target price on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Tuesday, July 10th. Finally, Deutsche Bank set a €84.00 ($97.67) target price on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Wednesday, July 11th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the stock. Fresenius SE & Co KGaA presently has a consensus rating of “Buy” and a consensus target price of €76.44 ($88.89).

FRE stock traded down €2.30 ($2.67) during midday trading on Thursday, hitting €60.52 ($70.37). The stock had a trading volume of 3,595,572 shares. Fresenius SE & Co KGaA has a 52 week low of €60.16 ($69.95) and a 52 week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Further Reading: Do You Need a Fiduciary?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply